- Cytoreductive surgery (CRS) is aimed at removing all visible peritoneal tumor implants. The goal of hyperthermic intraperitoneal chemotherapy (HIPEC) is to eliminate remnant microscopic tumor cells.
- The peritoneal carcinomatosis index (PCI) is used to quantify the extent of peritoneal carcinomatosis found during surgical exploration. With increasing involvement of peritoneal carcinomatosis, patient survival decreases.
- Multimodal imaging and diagnostic laparoscopy are essential to provide the surgeon with a detailed preoperative assessment of peritoneal disease, as well as the calculation of the radiologic PCI.
- CRS plus HIPEC should be preferentially offered to patients with minimal intraperitoneal tumor burden and the possibility of complete surgical resection of gross peritoneal disease.